Home/Filings/4/0001140361-17-011623
4//SEC Filing

Emergent BioSolutions Inc. 4

Accession 0001140361-17-011623

$EBSCIK 0001367644operating

Filed

Mar 9, 7:00 PM ET

Accepted

Mar 10, 4:18 PM ET

Size

12.9 KB

Accession

0001140361-17-011623

Insider Transaction Report

Form 4
Period: 2017-03-08
Transactions
  • Other

    Common Stock

    2016-08-01+45317,404 total
  • Other

    Common Stock

    2016-08-01+60418,008 total
  • Sale

    Common Stock

    2017-03-08$31.27/sh2,576$80,55816,009 total
  • Other

    Common Stock

    2016-08-01+57718,585 total
  • Other

    Employee Stock Option (Right to buy)

    2016-08-01+90510,305 total
    Exercise: $25.47Exp: 2022-01-21Common Stock (10,305 underlying)
Footnotes (6)
  • [F1]In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in January 2018.
  • [F2]In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018.
  • [F3]In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.
  • [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.25 to $31.32, inclusive.
  • [F5]Consists of an option granted on January 22, 2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
  • [F6]The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

Documents

1 file

Issuer

Emergent BioSolutions Inc.

CIK 0001367644

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001367644

Filing Metadata

Form type
4
Filed
Mar 9, 7:00 PM ET
Accepted
Mar 10, 4:18 PM ET
Size
12.9 KB